Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ANRO
ANRO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ANRO News
Alto Neuroscience CEO Amit Etkin Receives Transformational Research Award
May 15 2026
Newsfilter
Alto Neuroscience Reports Q1 2026 Financial Results
May 13 2026
seekingalpha
Major Wall Street Rating Updates
May 05 2026
CNBC
US Stocks Close Mixed Amid Oil Surge and Economic Data
Apr 02 2026
NASDAQ.COM
Analysis of ALTO-101 Clinical Trial Failure Impact
Apr 02 2026
stocktwits
Stock Markets Pressured by Soaring Oil Prices
Apr 02 2026
NASDAQ.COM
US Stocks Plummet as Oil Prices Surge
Apr 02 2026
NASDAQ.COM
Alto Neuroscience's Schizophrenia Drug Fails Mid-Stage Study
Apr 01 2026
stocktwits
ALTO-101 Clinical Trial Results Update
Apr 01 2026
Newsfilter
Alto Neuroscience Secures $120 Million PIPE Financing for ALTO-207 Development
Mar 16 2026
seekingalpha
Alto Secures $120 Million Financing to Advance ALTO-207 Development
Mar 16 2026
Newsfilter
Alto Neuroscience Reports FY EPS Beat and Strong Cash Position
Mar 16 2026
seekingalpha
Alto Acquires ALTO-207 to Address Treatment-Resistant Depression
Mar 16 2026
Newsfilter
Alto Neuroscience to Participate in Virtual Forum
Mar 13 2026
Newsfilter
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
Feb 26 2026
PRnewswire
Helus Pharma Achieves Breakthrough in Depression Treatment
Feb 26 2026
Newsfilter
Show More News
